These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 32367667

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy.
    Zhao L, Qu X, Wu Z, Li Y, Zhang X, Guo W.
    Aging (Albany NY); 2020 Jul 22; 12(14):14556-14568. PubMed ID: 32694238
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations.
    Geng H, Li S, Guo Y, Yan F, Han Y, Xu M, Cui Y.
    Cancer Biomark; 2020 Jul 22; 27(4):525-532. PubMed ID: 32083571
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma.
    Cheng X, Yin H, Fu J, Chen C, An J, Guan J, Duan R, Li H, Shen H.
    J Cancer Res Clin Oncol; 2019 Apr 22; 145(4):1027-1035. PubMed ID: 30810839
    [Abstract] [Full Text] [Related]

  • 27. Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression.
    Sestokaite A, Gedvilaite V, Cicenas S, Sabaliauskaite R, Jarmalaite S.
    Int J Mol Sci; 2023 Apr 09; 24(8):. PubMed ID: 37108122
    [Abstract] [Full Text] [Related]

  • 28. TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC.
    Feng H, Xu H, Shi X, Ding G, Yan C, Li L, Jian Z, Yang X, Guo H, Li F, Zhang J, Ren X.
    Front Biosci (Landmark Ed); 2023 Jul 24; 28(7):147. PubMed ID: 37525904
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
    Zhang Q, Sun T, Kang P, Qian K, Deng B, Zhou J, Wang R, Jiang B, Li K, Liu F, Wu S, Tan Q.
    Cancer Chemother Pharmacol; 2016 Mar 24; 77(3):583-93. PubMed ID: 26842788
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Prognostic significance of TP53 and PIK3CA mutations analyzed by next-generation sequencing in breast cancer.
    Choi JH, Yu J, Jung M, Jekal J, Kim KS, Jung SU.
    Medicine (Baltimore); 2023 Sep 22; 102(38):e35267. PubMed ID: 37747019
    [Abstract] [Full Text] [Related]

  • 36. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
    Sclafani F, Wilson SH, Cunningham D, Gonzalez De Castro D, Kalaitzaki E, Begum R, Wotherspoon A, Capdevila J, Glimelius B, Roselló S, Thomas J, Tait D, Brown G, Oates J, Chau I.
    Int J Cancer; 2020 Jan 01; 146(1):94-102. PubMed ID: 31199501
    [Abstract] [Full Text] [Related]

  • 37. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG, Catalan-Latorre A, Brugarolas A.
    BMC Cancer; 2021 Apr 20; 21(1):432. PubMed ID: 33879103
    [Abstract] [Full Text] [Related]

  • 38. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Park JH, Ahn JH, Kim JE, Jung KH, Gong G, Lee HJ, Son BH, Ahn SH, Kim HH, Shin HJ, Moon DH, Kim D, Kim SB.
    Anticancer Res; 2020 Oct 20; 40(10):5883-5893. PubMed ID: 32988919
    [Abstract] [Full Text] [Related]

  • 39. All-Exon TP53 Sequencing and Protein Phenotype Analysis Accurately Predict Clinical Outcome after Surgical Treatment of Head and Neck Squamous Cell Carcinoma.
    Kobayashi K, Yoshimoto S, Matsumoto F, Ando M, Murakami N, Omura G, Fukasawa M, Matsumoto Y, Matsumura S, Akamatsu M, Hiraoka N, Eigitsu R, Mori T.
    Ann Surg Oncol; 2019 Jul 20; 26(7):2294-2303. PubMed ID: 30900104
    [Abstract] [Full Text] [Related]

  • 40. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C, Kagara N, Shimazu K, Shimomura A, Naoi Y, Shimoda M, Kim SJ, Noguchi S.
    Clin Breast Cancer; 2016 Oct 20; 16(5):418-423. PubMed ID: 27265061
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.